INTRODUCTION
Hepatocellular carcinoma (HCC) is a universal malignant tumor with poor prognosis. It is the third cause of cancer mortality after lung cancer and stomach cancer globally, also in Korea [1] . Although there have been significant developments in therapies for HCC including surgery, transarterial chemoembolization, radiofrequency thermal ablation, and multikinase inhibitors (sorafenib, sunitinib, etc.), HCC remains a lethal disease [2, 3] . Accordingly, discovery of new therapeutic targets and biomarkers for early diagnosis and prognosis prediction of HCC with development of gene and expression analysis comes to the forefront [4] [5] [6] .
Sal-like protein 4 (SALL4) is a human homolog to Drosophaila spalt. In humans, SALL4 is one of several transcription factors which are a valuable part of the self-renewal of embryonic stem cells as well as in embryonic development [7] [8] [9] . Many published studies showed SALL4 is an oncogene in leukemia and other various types of cancers like non-small-cell lung cancers (NSCLC), breast cancer, and testicular germ cell tumors [10] [11] [12] . In the liver, elevated SALL4 was found in fetal liver, and SALL4 gradually diminishes during development [13] . Yong et al. [14] showed unique expression patterns of SALL4 in human livers at various stages -expressed as an oncofetal protein in HCC, activated in liver of fetus, and inactivated in liver of adult.
Recently, outstanding studies have suggested SALL4, an oncofetal gene, as a prognosis biomarker in HCC. With that, previous studies that were published showed SALL4 expression in HCC patients could potentially be a new treatment target for HCC. However, there were many debates in study groups on the difference in terms of etiologic causes between Western and Asian HCC and detection method. Hence, general application of SALL4 for HCC is needed to confirm the diagnostic and therapeutic efficacy of SALL4 [14] [15] [16] [17] .
Therefore, we tried to verify the features of SALL4 immunoreactivity and its clinical correlation in Korean HCC patients. We will use SALL4 as a new therapeutic target for HCC based on this study.
METHODS

Patients and tissue specimens
A total of 213 patients with HCCs with complete clinicopathologic data were collected. Patients were underwent curative surgery at the department of surgery, Hanyang University Seoul Hospital between January 1991 and September 2013. Medical records were reviewed and characteristic data (age, sex), pathologic data (tumor size, tumor number, histologic grade, vascular invasion, perineural invasion), and clinical data (α-FP, survival, ascite, albumin, bilirubin, encephalopathy, prothrombin time) were extracted.
Tissue microarray construction
The pathologist (S.S.P.) reviewed the histology of each case, and selected the representative, properly fixed, and viable areas for tissue microarray (TMA) construction. Single 2.0-mm tissue cores were sampled from donor blocks and transferred to recipient blocks.
Immunohistochemical staining
The 4-µm-thick tissue sections from TMA blocks were deparaffinized with xylene and rehydrated in a graduated series of ethanol. For heat-induced antigen retrieval, the following conditions were applied for optimization: autoclave heating at 100 o C for 30 minutes; and microwave heating for 
Interpretation of SALL4 expression
The immunohistochemical staining slides were interpreted by 2 pathologists who were blinded to clinical data. The interpretation was based on a semiquantitative system; the staining intensity and proportion. Staining intensity was scored as 0 (negative), 1 (weak), 2 (intermediate), 3 (strong) . Staining proportion was scored as 0 (<10%), 1 (11%-25%), 2 (26%-50%), 3 (51%-75%), 4 (76%-100%) according to the percentage of immunoreactive tumor cells. The final score as immunoreactive score (IRS) was calculated by multiplying intensity score by proportion score (Fig. 1) . xPositive SALL4 expression was defined as tumor cells having nuclear staining with minimal background and 1 or more IRS.
Statistical analysis
The appropriate statistical analysis was used with IBM SPSS ver. 18.0 (IBM Co., Armonk, NY, USA). The correlation between the SALL4 expression and tumor size, α-FP was evaluated using 
RESULTS
Demographic and clinical data of the patients Table 1 summarizes the general characteristics of HCC patients. Of the 213 patients who were included in this TMA analysis, 167 patients (78.4%) were male and 46 patients (21.6%) were female. The mean age was 55.39 years (range, 15-87 years) and the mean survival was 49.97 months (range, 0-278 months). The average tumor size of the largest tumor in patients were 4.76 cm (range, 0.7-22 cm) and the majority (n = 176, 82.6%) of patients had single tumor. The mean serum α-FP level was 715.11 ng/mL (range, 1-11,000 ng/mL). 
Immunohistochemical staining for SALL4 in human HCC tissues
Using the semiquantative scoring system for SALL4 as described above, among 213 HCC TMA specimens, 50 (23.5%) showed scores of ≥1 (range, 1 to 9). According to the method of antigen retrieval, there was difference in staining intensity; Autoclave heating at 100 o C for 30 minutes (50 cases) increased the positive expression cases than heating for 12 minutes (2 cases) in sodium citrate buffer (Fig. 2) .
Correlation between SALL4 expression and clinicopathological parameters in HCC
It demonstrated that the SALL4-positive HCCs had considerably higher tumor grade (P < 0.001) compared with SALL4-negative HCCs. On the clinicopathologic analyses, relevance between SALL4 and clinicopathologic features were not found in microscopic and macroscopic vessel invasions, perineural invasions, but SALL4 and α-FP correlated significantly (P = 0.002) ( Table 2 ).
Positive SALL4 expression is a prognostic marker of overall survival in large HCC
Following the univariate analysis, SALL4 immunoreactivity was associated with prognosis. There was no considerable correlation with SALL4 and prognosis. However, survival analysis showed positive correlation with largest tumor size (P = 0.005), and SALL4 immunoreactivity in T3 and T4 HCC were correlated with poor prognosis (Fig. 3) .
DISCUSSION
HCC is a lethal disease with a high mortality among various cancers [18] . In this study, we show the features of SALL4 immunoreactivity and its clinical correlation in Korean HCC patients.
SALL4 immunoreactivity (defined as IRS ≥1) was seen in 50 cases of a total 213 cases in our analysis. In this study, histologic grade and α-FP were correlated significantly with SALL4. Correlations between SALL4 and clinicopathologic factors were not seen in AJCC stage, Okuda stage, vessel invasion, perineural invasion, or tumor size. In the survival analysis, positive correlation with large tumor size, histologic grade, and SALL4 immunoreactivity in T3 and T4 were correlated with poor prognosis.
From these results, we have several significant clinical suggestions. SALL4 immunohistochemisty correlates with aggressive progress and poor prognosis of HCC in some cases. Therefore, it shows the potency of SALL4 as a prognostic biomarker in HCC, and furthermore as a therapeutic target for HCC.
However, there are some limitations in this study. First, the TMA of HCC in this study consisted of resected specimens of HCC patients from only one center in Korea without a database of underlying disease. Some studies published previously showed that there were differences of SALL4 expression according to ethnicity or underlying disease like HBV [14, 15] . Second, immunohistochemical staining method is slightly different from previous studies in areas of antigen retrieval and so on. Also, interpretation of SALL4 expression includes injection of pathologists' subjectivity. Any ideal prognostic or therapeutic biomarker should be performed easily with accurate and simple methods and have high sensitivity and specificity. From now on, the objectification of SALL4 expression is needed with further study.
In summary, we found that positive immunostaining of SALL4 is correlated with poor patient survival outcome in large and undifferentiated Korean HCC. SALL4 expression showed close relationship with clinical outcomes of HCCs in Korean patients. Further careful well-designed study for SALL4 stem cell marker as a biomarker for HCCs should be done with multinational studies for general application of SALL4.
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